Plasma levels of asymmetric dimethylarginine in cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy

Cerebrovascular Diseases

Volumn 26, Issue 6, 2008, Pages 636-640

  Rufa, Alessandra ^a   Blardi, Patrizia ^a   De Lalla, Arianna ^a   Cevenini, Gabriele ^a   De Stefano, Nicola ^a   Zicari, Enza ^a   Auteri, Alberto ^a   Federico, Antonio ^a   Dotti, Maria Teresa ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Asymmetric dimethylarginine; Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; Genetic ischemic stroke; Nitric oxide synthase inhibitor

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE;

ADOLESCENT; ADULT; ARTICLE; BRAIN DAMAGE; CADASIL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK;

ADULT; ANTIHYPERTENSIVE AGENTS; ARGININE; BIOLOGICAL MARKERS; BRAIN; CADASIL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RECEPTORS, NOTCH; RISK FACTORS;

EID: 55149095686     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000166840     Document Type: Article

References (21)

1. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cécillion M, Marechal E, Maciazek J, Vayssiere C, Cruaud C, Cabanis EA, Rouchoux MM, Weissenbach J, Bach JF, Bousser MG, Tournier-Lasserve E: Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-710.
2. Dichgans M: CADASIL: a monogenic condition causing stroke and subcortical vascular dementia. Cerebrovasc Dis 2002;13:37-41.
3. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L: Impaired endothelial function of forearm resistance arteries in CADASIL patients. Stroke 2007;38:2692-2697.
4. Dubroca C, Lacombe P, Domenga V, Maciazek J, Levy B, Tournier-Lasserve E, Joutel A, Henrion D: Impaired vascular mechanotransduction in a transgenic mouse model of CADASIL arteriopathy. Stroke 2005;36:113-117.
5. Ruchoux MM, Maurage CA: Endothelial changes in muscle and skin biopsies in patients with CADASIL. Neuropathol Appl Neurobiol 1997;23:60-65.
6. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-2074.
7. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-177.
8. Tran CT, Leiper JM, Vallance P: The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003;4:33-40.
9. Khan U, Hassan A, Vallance P, Markus H: Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007;38:411-413.
10. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA: Determination of arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002;303:131-137.
11. Wanby P, Teerlink T, Brudin L, Brattstrom L, Nilsson I, Palmqvist P, Carlsson M: Asymmetric dimethylarginine (ADMA) as a risk marker for stoke and TIA in a Swedish population. Atherosclerosis 2006;185:271-277.
12. Van Waesberghe JH, van Walerveen MA, Castelijns JA, Scheltens P, Nijeholt GJ, Polman CH, Barkhof F: Pattern of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675-683.
13. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM: ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006;37:2024-2029.
14. Hassain A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffry S, Bamford JM, Marcus HS: Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004;127:212-219.
15. Gobron C, Vahedi K, Vicaut E, Stucker O, Laemmel E, Baudry N, Bousser MG, Chabriat H: Characteristic features of in vivo skin microvascular reactivity in CADASIL. J Cereb Blood Flow Metab 2007;27:250-257.
16. Zsuga J, Torok J, Magyar MT, Valikovics A, Geszteliyi R, Keki S, Csiba L, Zsuga M, Bereczki D: Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early onset atherosclerosis. Cerebrovasc Dis 2007;23:388-394.
17. Dayoub H, Rodionov R, Lynch C, Cooke JP, Arning E, Bottiglieri T, Lentz SR, Faraci FM: Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke 2008;39:180-184.
18. Lenz SR: Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005;3:1646-1654.
19. Singhal S, Bevan S, Barrick, Rich P, Markus HS: The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004;127:2031-2038.
20. Finsterer J: Neuromuscular implications in CADASIL. Cerebrovasc Dis 2007;24:401-404.
21. Zimmermann C, Wimmer M, Haberl RL: L-Arginine-mediated vasoreactivity in patients with risk of stroke. Cerebrovasc Dis 2004;17:128-133.